Healthcare: CardioComm Solutions Contracts Distribution Broker for Launch of the HeartCheck™ PEN to U.S. Retailers
Asset Management and Technical Logistics Services Secured for the Sale of the HeartCheck™ Product Line to Consumers and Commercial Buyers in the United States Read More
';
MMRGlobal to Present the Future of Personal Health at B. Riley & Co. Investor Conference - 18 May 2012, 10:44 am
Cynapsus Therapeutics Retains US Investor Relations Firm - 17 May 2012, 10:54 am
TORONTO, ONTARIO--(Marketwire - May 16, 2012) - Cynapsus Therapeutics Inc. ("Cynapsus") (http://www.cynapsus.ca) (TSX VENTURE:CTH) today announced that it has retained JSDC, Inc. ("JSDC") to provide US-based investor relations services for the Company. Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. Over one million people in the United States and an estimated 5 million people globally suffer from Parkinson's disease.
LED Medical Diagnostics Reports 2012 First Quarter Results - 15 May 2012, 11:56 am
BURNABY, BRITISH COLUMBIA--(Marketwire - May 15, 2012) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD) ("LED" or the "Company") today announced its financial results for the first quarter ended March 31, 2012, reported in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS"). The Company's results are presented in comparison to the three months ended December 31, 2011 and the three months ended March 31, 2011, also in accordance with IFRS.
MMRGlobal Signs Reseller Agreements With Patient-Advocate.com and Premier Health Advocates Under Rapid Revenue Prog... - 14 May 2012, 11:32 am
OS ANGELES, CA--(Marketwire - May 14, 2012) - MMRGlobal, Inc. (OTCBB: MMRF) ("MMR"), today announced that it had signed reseller agreements with two nationally known Patient Advocate Organizations: Premier Health Advocates and Patient-Advocate.com.
VentriPoint VMS™ Heart Analysis System Installed at Allegheny General Hospital in Pittsburgh - 11 May 2012, 10:53 am
SEATTLE, WASHINGTON--(Marketwire - May 11, 2012) - VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF) has installed its latest version of the VMS™ heart analysis system at Allegheny General Hospital in Pittsburgh to support its clinical trials program and for other research purposes. The first Pulmonary Arterial Hypertension (PAH) patient has completed the MRI and VMS™ scans.
Elevation reveals positive results from EP-101 study - 17 May 2012, 06:00 pm
Elevation Pharmaceuticals has announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema. Read more...
Nucynta ER tablets show efficacy in pain management - 17 May 2012, 06:00 pm
Janssen Pharmaceuticals' Nucynta (tapentadol) extended-release (ER) tablets have been found effective in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neurophysiology (DPN) compared to placebo. Read more...
Pinpoint accuracy: programmable nanoparticles and future cancer treatments - 17 May 2012, 06:00 pm
Most cancer drugs are not as effective as doctors would like them to be because the amount that can be administered is limited by toxicity. But a new technology, Accurin, which utilises programmable nanoparticles, is set to change all that. Elly Earl… Read more...
Tivozanib drug shows superior PFS over sorafenib in Phase 3 study - 16 May 2012, 06:00 pm
Aveo Oncology and Astellas Pharma have announced positive findings from the Tivozanib Versus Sorafenib in 1st line Advanced RCC (TIVO-1) study of its investigational agent tivozanib. Read more...
Achaogen plazomicin drug meets Phase 2 study endpoints - 16 May 2012, 06:00 pm
Achaogen's plazomicin (ACHN-490) drug has met all the objectives in the multinational Phase 2 study conducted in adults with complicated urinary tract infections (cUTI) and acute pyelonephritis. Read more...
Sutent (Sunitinib Malate) - Treatment for Pancreatic Neuroendocrine Tumours - 16 May 2012, 06:00 pm
Sutent (sunitinib malate) is an oral multikinase inhibitor which is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumours (NET). Read more...